Evidence map›Paper›PMID 41870616›Full record

ArticleJournal of gastroenterology2026

Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests.

Kazuhito Kawata, Hirokazu Takahashi, Taeang Arai, Yuya Seko, Takeshi Chida, Hidenao Noritake, Hidenori Toyoda, Hideki Hayashi, Kanji Yamaguchi, Michihiro Iwaki and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hirokazu TakahashiDepartment of Hepatology, Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan. takahas2@cc.saga-u.ac.jp.ORCID http://orcid.org/0000-0003-1900-4389
Taeang AraiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Yuya SekoDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takeshi ChidaHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hidenao NoritakeHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Hideki HayashiDepartment of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
Kanji YamaguchiDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Michihiro IwakiDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masato YonedaDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Toshihide ShimaDepartment of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
Hideki FujiiDepartment of Hepatology, Osaka Metropolitan University, Osaka, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Kengo TomitaDepartment of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
Miwa KawanakaDepartment of Gastroenterology and Hepatology, Okayama University, Okayama, Japan.
Yuichi YoshidaDepartment of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan.
Tadashi IkegamiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan.
Kazuo NotsumataDepartment of Gastroenterology, Municipal Tsuruga Hospital, Fukui, Japan.
Satoshi OedaDepartment of Hepatology, Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Masanori AtsukawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Yoshihiro KamadaDepartment of Advanced Metabolic Hepatology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Yoshio SumidaGraduate School of Healthcare Management, International University of Healthcare and Welfare, Tokyo, Japan.
Hideaki FukushimaDiagnostics Business Area, Siemens Healthcare Diagnostics K.K, Tokyo, Japan.
Eiji MiyoshiDepartment of Molecular Biochemistry & Clinical Investigation, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Shinichi AishimaDepartment of Scientific Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takeshi OkanoueDepartment of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
Yoshito ItohDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Atsushi NakajimaDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of each factor and the number of positive criteria on pathogenesis and the diagnostic performance of non-invasive tests (NITs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. This study aimed to investigate the association between the cardiometabolic criteria and the clinical features.

methodsThis retrospective study investigated clinicopathological characteristics and the diagnostic performance of the Enhanced Liver Fibrosis (ELF) test, fibrosis-4 (FIB-4) index, and nonalcoholic fatty liver disease fibrosis score (NFS) according to the factors and the number of positive cardiometabolic criteria in 1,038 patients with biopsy-proven MASLD.

resultsHypertension is a significant risk factor for progression to advanced fibrosis and at-risk metabolic dysfunction-associated steatohepatitis (MASH) in male patients. In contrast, no significant risk factor was identified in female patients. The incidence of advanced fibrosis increased significantly in patients with three or more positive criteria. Similarly, the incidence of at-risk MASH increased significantly in a stepwise manner with the number of positive cardiometabolic criteria. The diagnostic performance of the ELF test for advanced fibrosis exceeded that of the FIB-4 index and NFS for all factors except hypertension. Regardless of the number of positive cardiometabolic criteria, the ELF test demonstrated a superior diagnostic performance for advanced fibrosis.

conclusionsMASLD with hypertension in male patients or a higher number of positive cardiometabolic criteria constitutes a significant risk for advanced fibrosis or at-risk MASH. The ELF test is a valuable tool for diagnosing advanced fibrosis progression regardless of individual factors or the number of positive cardiometabolic criteria.

Indexed as

HypertensionLiver CirrhosisNon-alcoholic Fatty Liver DiseaseAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSex FactorsCardiometabolic criteriaELF testMASLDNITs

Identifiers

PMID41870616

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.